Allogeneic transplantation using either unrelated donor or cord blood grafts "can produce extended and even curative long-term survival" in patients over age 50 with AML in first complete remission, according to a study of 740 transplants reported to CIBMTR (Center for International Blood and Marrow Transplant Research) and Eurocord. Three-year survival of 8/8 unrelated donor, 7/8 unrelated donor, and cord blood transplant recipients were 43%, 37%, and 30%, respectively, and the difference in survival between 8/8 unrelated donor and cord blood was statistically significant (p=0.002). The researchers concluded that "allogeneic transplantation need not be withheld from older patients and for clinically suitable AML patients."
Weisdorf DJ, et al. Biol Blood Marrow TransplantChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Unrelated Donor, Cord Blood Grafts Yield Extended Survival in Older AML Patients
Feb 2014